You expect to have your blood pressure checked and treated when you visit the doctor’s office or urgent care clinic. But what about the barbershop? New research shows that besides delivering the customary shave and a haircut, barbers might be able to play a significant role in helping control high blood pressure.
High blood pressure, or hypertension, is a particularly serious health problem among non-Hispanic black men. So, in a study involving 52 black-owned barbershops in the Los Angeles area, barbers encouraged their regular, black male patrons, ages 35 to 79, to get their blood pressure checked at their shops . Nearly 320 men turned out to have uncontrolled hypertension and enrolled in the study. In a randomized manner, barbers then encouraged these men to do one of two things: attend one-on-one barbershop meetings with pharmacists who could prescribe blood pressure medicines, or set up appointments with their own doctors and consider making lifestyle changes.
The result? More than 63 percent of the men who received medications prescribed by specially-trained pharmacists lowered their blood pressure to healthy levels within 6 months, compared to less than 12 percent of those who went to see their doctors. The findings serve as a reminder that helping people get healthier doesn’t always require technological advances. Sometimes it may just involve developing more effective ways of getting proven therapy to at-risk communities.
Tags: African American health, All of Us Research Program, barbers, barbershops, black barbershops, blood pressure, cardiology, clinical trial, Dallas Heart Study, diagnostics, health disparities, health education, healthcare delivery, heart, heart attack, high blood pressure, hypertension, lifestyle, pharmacists, stroke, systolic
For obese people with diabetes, doctors have increasingly been offering gastric bypass surgery as a way to lose weight and control blood glucose levels. Short-term results are often impressive, but questions have remained about the long-term benefits of such operations. Now, a large, international study has some answers.
Soon after gastric bypass surgery, about 50 percent of folks not only lost weight but they also showed well-controlled blood glucose, cholesterol, and blood pressure. The good news is that five years later about half of those who originally showed those broad benefits of surgery maintained that healthy profile. The not-so-good news is that the other half, while they generally continued to sustain weight loss and better glucose control, began to show signs of increasing risk for cardiovascular complications.
Tags: bariatric surgery, blood glucose, blood pressure, cardiovascular disease, cholesterol, clinical trial, composite triple endpoint, diabetes, gastric bypass, heart attack, heart disease, hemoglobin A1C, obesity, Roux-en-Y procedure, sleeve gastrectomy, stroke, surgery, type 2 diabetes, weight
When the time comes to get relief from a dental problem, we are all glad that dentistry has come so far—much of the progress based on research supported by NIH’s National Institute of Dental and Craniofacial Research. Still, almost no one looks forward to getting a root canal. Not only can the dental procedure be uncomfortable and costly, there’s also a risk of failure due to infection or other complications. But some NIH-supported researchers have now come up with what may prove to be a dazzling strategy for reducing that risk: nanodiamonds!
That’s right, these researchers decided to add tiny diamonds—so small that millions could fit on the head of the pin—to the standard filler that dentists use to seal off a tooth’s root. Not only are these nanodiamonds extremely strong, they have unique properties that make them very attractive vehicles for delivering drugs, including antimicrobials that help fight infections of the sealed root canal.
Tags: cancer, chemotherapy, cleft lip and palate, clinical trial, dental care, dental health, dentist, dentistry, diamonds, endodontics, gutta percha, liver cancer, nanodiamonds, Nanomedicine, nanoparticles, nanotechnology, NDGP, periodontal disease, root canal, teeth, tooth, tooth infection, tooth root
Every year, thousands of older Americans require emergency treatment to stop bleeding caused by taking warfarin, a frequently prescribed blood-thinning pill. My own mother received this drug in her later years, and her doctors encountered significant challenges getting the dose right. The problem is too much warfarin causes potentially serious bleeding, while too little leaves those who need the drug vulnerable to developing life-threatening clots in their legs or heart. The difference between too little and too much is distressingly small. But what if before writing a prescription, doctors could test for known genetic markers to help them gauge the amount of warfarin that a person should take?
Such tests have been available to doctors and patients for a few years, but they have not been widely used. The recent results of a national clinical trial offer some of the most convincing evidence that it’s time for that to change. In this study of 1,650 older adults undergoing elective hip or knee surgery, patients whose genetic makeup was used to help determine their dose of warfarin were less likely to suffer adverse events, including major bleeding. This trial marks an encouraging success story for the emerging field of pharmacogenomics, the study of how the variations in our genes affect our responses to medicines.
Tags: blood, blood thinner, blood-thinning drugs, clinical trial, coagulation, CYP2C9, CYP4F2, drug safety, drugs, FDA, Genetic InFormatics Trial (GIFT) of Warfarin Therapy to Prevent Deep Venous Thrombosis, geriatrics, GIFT, hematology, hip replacement, knee replacement, medicine, NIH All Of Us Research Program, pharmacogenomics, precision medicine, prescription drugs, randomized clinical trial, vitamin K, VKORC1, warfarin, warfarin dosing, warfarin sensitivity
Vaccines are one of biomedicine’s most powerful and successful tools for protecting against infectious diseases. While we currently have safe and effective vaccines to prevent measles, mumps, and a great many other common childhood diseases, we still lack a vaccine to guard against respiratory syncytial virus (RSV)—a leading cause of pneumonia among infants and young children.
Each year, more than 2 million U.S. children under the age of 5 require medical care for pneumonia and other potentially life-threatening lower respiratory infections caused by RSV [1,2]. Worldwide, the situation is even worse, with more than 30 million infections estimated to occur annually, most among kids in developing countries, where as many as 200,000 deaths may result . So, I’m pleased to report some significant progress in biomedical research’s long battle against RSV: encouraging early results from a clinical trial of an experimental vaccine specifically designed to outwit the virus.
Tags: childhood disease, childhood infectious diseases, childhood vaccine, clinical trial, CRADA, genetic engineering, global health, immunity, live vaccine, M2-2 gene, neutralizing antibodies, pneumonia, respiratory diseases, respiratory syncytial virus, RSV, RSV MEDI ΔM2-2, RSV vaccine, translational medicine, vaccine, virology